Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medexus Pharmaceuticals Inc. (MDP.TO)
Toronto, ON, CA
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.52% | -2.27% | -2.02% | +34.72% | +39.57% | +33.33% | +25.97% | +210.40% | -47.07% | +52.16% | -48.27% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-8.3% Q1'26: -0.4% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-187.5% Q1'26: -277.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+2.6% Q1'26: -45.5% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+3.0% Q1'26: +4.9% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+4.5% Q1'26: +6.7% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+21.9% Q1'26: +20.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.76× Q1'26: 11.72× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 3 EPS Ana. |
Mar 2027 5 Rev. Ana. 3 EPS Ana. |
Mar 2028 4 Rev. Ana. 2 EPS Ana. |
Mar 2029 3 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.21M
est: 4.41M (+40.9%)
|
10.01M
est: 9.04M (+10.8%)
|
33.86M
est: 25.10M (+34.9%)
|
74.36M
est: 51.09M (+45.5%)
|
79.66M
est: 86.51M (-7.9%)
|
76.70M
est: 75.13M (+2.1%)
|
108.10M
est: 107.59M (+0.5%)
|
113.05M
est: 79.57M (+42.1%)
|
108.33M
est: 109.35M (-0.9%)
|
100.06M
98.58M – 101.30M
-8.5% YoY
|
113.08M
104.92M – 119.11M
+13.0% YoY
|
137.99M
122.91M – 143.91M
+22.0% YoY
|
163.22M
148.06M – 170.98M
+18.3% YoY
|
177.10M
160.65M – 185.52M
+8.5% YoY
|
216.62M
196.50M – 226.92M
+22.3% YoY
|
| EBITDA |
-3.35M
est: 331.7K (-1,110.2%)
|
-2.06M
est: 680.1K (-403.6%)
|
1.67M
est: 1.89M (-11.5%)
|
3.78M
est: 3.85M (-1.7%)
|
-23.61M
est: 6.51M (-462.6%)
|
14.55M
est: 5.65M (+157.3%)
|
14.65M
est: 8.10M (+80.9%)
|
19.28M
est: 12.39M (+55.6%)
|
16.81M
est: 17.02M (-1.2%)
|
15.58M
15.34M – 15.77M
-8.5% YoY
|
17.60M
16.33M – 18.54M
+13.0% YoY
|
21.48M
19.13M – 22.40M
+22.0% YoY
|
25.41M
23.05M – 26.62M
+18.3% YoY
|
27.57M
25.01M – 28.88M
+8.5% YoY
|
33.72M
30.59M – 35.32M
+22.3% YoY
|
| EBIT |
-3.40M
est: -10.1K (-33,720.0%)
|
-2.30M
est: -20.6K (-11,040.1%)
|
-706.0K
est: -57.2K (-1,133.3%)
|
-1.48M
est: -116.5K (-1,166.6%)
|
-21.69M
est: -197.3K (-10,890.5%)
|
8.40M
est: -171.4K (+5,004.0%)
|
8.57M
est: -245.4K (+3,590.1%)
|
13.47M
est: 6.78M (+98.5%)
|
9.64M
est: 9.32M (+3.3%)
|
8.53M
8.41M – 8.64M
-8.5% YoY
|
9.64M
8.95M – 10.16M
+13.0% YoY
|
11.77M
10.48M – 12.27M
+22.0% YoY
|
13.92M
12.62M – 14.58M
+18.3% YoY
|
15.10M
13.70M – 15.82M
+8.5% YoY
|
18.47M
16.76M – 19.35M
+22.3% YoY
|
| Net Income |
-1.37M
est: -5.79M (+76.3%)
|
-3.48M
est: -6.26M (+44.4%)
|
-4.88M
est: -12.59M (+61.2%)
|
-4.70M
est: -4.57M (-3.0%)
|
-28.26M
est: -29.33M (+3.6%)
|
-2.88M
est: -3.18M (+9.6%)
|
1.22M
est: -8.70M (+114.0%)
|
-214.0K
est: 1.07M (-120.0%)
|
2.25M
est: 1.10M (+103.5%)
|
69.5K
-200.6K – 386.8K
-93.7% YoY
|
10.94M
5.46M – 16.41M
+15,628.0% YoY
|
16.88M
16.15M – 33.15M
+54.3% YoY
|
35.69M
29.78M – 41.60M
+111.5% YoY
|
41.51M
36.50M – 44.08M
+16.3% YoY
|
36.55M
32.14M – 38.81M
-11.9% YoY
|
| SGA |
5.10M
est: 1.83M (+178.7%)
|
6.09M
est: 3.75M (+62.2%)
|
15.62M
est: 10.43M (+49.7%)
|
28.93M
est: 21.23M (+36.3%)
|
36.17M
est: 35.94M (+0.6%)
|
44.03M
est: 31.21M (+41.1%)
|
48.25M
est: 44.70M (+7.9%)
|
38.44M
est: 33.27M (+15.5%)
|
36.15M
est: 45.73M (-20.9%)
|
41.84M
41.22M – 42.36M
-8.5% YoY
|
47.29M
43.88M – 49.81M
+13.0% YoY
|
57.71M
51.40M – 60.18M
+22.0% YoY
|
68.26M
61.92M – 71.50M
+18.3% YoY
|
74.06M
67.18M – 77.58M
+8.5% YoY
|
90.59M
82.18M – 94.90M
+22.3% YoY
|
| EPS |
-0.28
est: -0.22 (-28.2%)
|
-0.47
est: -0.24 (-99.1%)
|
-0.48
est: -0.48 (-1.0%)
|
-0.33
est: -0.17 (-91.6%)
|
-1.86
est: -1.11 (-68.1%)
|
-0.19
est: -0.12 (-58.2%)
|
0.08
est: -0.33 (+124.4%)
|
-0.01
est: 0.03 (-128.1%)
|
0.09
est: 0.04 (+155.7%)
|
0.00
-0.01 – 0.01
-88.7% YoY
|
0.29
0.17 – 0.51
+7,050.1% YoY
|
0.68
0.50 – 1.03
+137.7% YoY
|
1.10
0.92 – 1.29
+62.9% YoY
|
1.28
1.13 – 1.36
+16.3% YoY
|
1.13
0.99 – 1.20
-11.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 88.1K | 0.22% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 59.0K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kenneth d'Entremont | Chief Executive Officer & Director | 2M | male |
| Richard Labelle | Chief Operating Officer | 736.2K | male |
| Bill Poncy | Senior Vice President of Commercial Operations - United States | 606.1K | male |
| Ian C. Wildgoose Brown | General Counsel & Corporate Secretary | 596.1K | male |
| Brendon Buschman | Chief Financial Officer | 558.2K | male |
| Brian Peters | Vice President of Sales & Marketing - United States | 396.7K | male |
| Tina Byers | Executive of Investor Relations | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MDP.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
